We are deeply honoured to announce we have been awarded with the European Innovation Council Accelerator funding for our project MICK – translational microbiome platform.
The EIC Accelerator offers start-ups and SMEs grants of up to EUR 2.5 million combined with equity investments through the EIC Fund ranging from EUR 0.5 to EUR 15 million. In addition to financial support, all projects benefit from a range of Business Acceleration Services that provide access to leading expertise, corporates, investors and ecosystem actors.
The selection process is really competitive, over 4000 start-ups and SMEs from all over Europe sent their ideas to be considered for the grant. Sequentia was one of the 99 companies that were selected to benefit from the programme and be able to take MICK to the next level.
MICK is the first translational microbiome platform for healthcare practice. MICK translates the taxonomical and functional microbiome characterisation data into actionable information allowing healthcare professionals to use it in the clinical decision-making process.
Our project, MICK, was born as the result of the efforts of a hard-working, committed and passionate team and thanks to the key support of the EIC funding, MICK has the potential to become a cutting-edge solution for precision medicine in Europe.
With the award of this grant and during the next two years we will step forward our technology, perform further clinical validations, and advance our market readiness with the aim to become the ultimate microbiome software solution for healthcare in europe.
We want to congratulate the other winners, and thank the European Innovation Council for believing in the potential of our project.